Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1992 1
1996 1
2002 9
2003 7
2004 15
2005 19
2006 15
2007 18
2008 30
2009 23
2010 22
2011 22
2012 23
2013 14
2014 17
2015 14
2016 9
2017 12
2018 6
2019 11
2020 11
2021 12
2022 13
2023 9
2024 3

Text availability

Article attribute

Article type

Publication date

Search Results

312 results

Results by year

Filters applied: . Clear all
Page 1
Examining the Burden of Potentially Avoidable Heart Failure Hospitalizations.
Zilberberg MD, Nathanson BH, Sulham K, Mohr JF, Goodwin M, Shorr AF. Zilberberg MD, et al. Among authors: shorr af. Clinicoecon Outcomes Res. 2023 Sep 29;15:721-731. doi: 10.2147/CEOR.S423868. eCollection 2023. Clinicoecon Outcomes Res. 2023. PMID: 37795407 Free PMC article.
Participant- and Disease-Related Factors as Independent Predictors of Treatment Outcomes in the RESTORE-IMI 2 Clinical Trial: A Multivariable Regression Analysis.
Martin-Loeches I, Shorr AF, Kollef MH, Du J, Losada MC, Paschke A, DeRyke CA, Wong M, Jensen EH, Chen LF. Martin-Loeches I, et al. Among authors: shorr af. Open Forum Infect Dis. 2023 May 4;10(6):ofad225. doi: 10.1093/ofid/ofad225. eCollection 2023 Jun. Open Forum Infect Dis. 2023. PMID: 37383243 Free PMC article.
Efficacy and safety of sulbactam-durlobactam versus colistin for the treatment of patients with serious infections caused by Acinetobacter baumannii-calcoaceticus complex: a multicentre, randomised, active-controlled, phase 3, non-inferiority clinical trial (ATTACK).
Kaye KS, Shorr AF, Wunderink RG, Du B, Poirier GE, Rana K, Miller A, Lewis D, O'Donnell J, Chen L, Reinhart H, Srinivasan S, Isaacs R, Altarac D. Kaye KS, et al. Among authors: shorr af. Lancet Infect Dis. 2023 Sep;23(9):1072-1084. doi: 10.1016/S1473-3099(23)00184-6. Epub 2023 May 11. Lancet Infect Dis. 2023. PMID: 37182534 Clinical Trial.
312 results